30 U.S. states agreed to an $8 million dollar settlement with Bayer Corp. last week after alleging the company had failed to adequately warn consumers about the risks associated with its drug Baycol.
The U.S. Court of Appeals for the District of Columbia on Nov. 14 upheld a district court's ruling that gave Teva Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd. exclusive rights to sell generic forms of Zocor.
Florida resident Michael Allyn Carlow pleaded guilty Nov. 3 in Kansas City, Missouri, before U.S. District Judge Ortrie Smith for his role in a massive $42 million scheme to sell illegally imported and counterfeit Lipitor.
A Miami, Florida, resident has received sentences totaling 13½ years in federal prison for his role in a scheme to sell genuine Lipitor intended for South American markets and counterfeit Lipitor manufactured in Costa Rica.
The U.S. Court of Appeals for the Federal Circuit on Oct. 23 denied a petition by Ranbaxy Laboratories for a rehearing of an August decision giving Pfizer exclusivity over Lipitor's active ingredient until 2010.
Douglas C. Albers avoided prosecution for sales of counterfeit Lipitor by pleading guilty Oct. 18 in a Kansas City, Missouri, District Court to one count each of selling counterfeit Neupogen and misbranded Neupogen.
Twenty-nine plaintiffs from seven states have filed suit against Pfizer, alleging the drug maker concealed dangerous health risks linked to its popular cholesterol-reducing drug Lipitor.
Miami resident Iggy Santisteban was sentenced September 8 to 37 months in federal prison for his part in a multimillion dollar conspiracy to illegally import, counterfeit, and sell Lipitor and other drugs.
Miami resident Alexander Nassar pleaded guilty August 28 in a Kansas City, Missouri, federal court to participating in a multimillion-dollar conspiracy to import and sell stolen and counterfeit Lipitor.
On August 2 the U.S. Court of Appeals upheld one patent of drug maker Pfizer's popular cholesterol-lowering drug Lipitor, but ruled a second patent invalid on technical grounds.
Seventeen new lawsuits filed July 14 in New York State Supreme Court allege that pharmaceutical maker Pfizer failed to provide physicians and patients adequate warning about the possible negative side effects of its cholesterol-lowering drug Lipitor.
Florida resident Domingo Gonzalez was sentenced to nine-and-a-half years in prison and ordered to pay $1.8 million after pleading guilty to selling more than 4 million counterfeit Lipitor tablets between December 2002 and August 2005.
Attorney Mark Jay Krum filed lawsuits on behalf of two clients who claim that drug maker Pfizer withheld information about possible debilitating side effects associated with its popular cholesterol-reducing drug Lipitor.
New York State Comptroller Alan Hevesi announced June 1 that he plans to replace the law firm Milberg Weiss Bershad & Schulman in the state's class action suit against the pharmaceutical company Bayer AG.
U.S. District Judge Richard Roberts ruled May 1 that the FDA overstepped Congress' authority when it denied two drug makers' claim to six months of exclusive sales rights for generic versions of Merck's cholesterol-fighting drug Zocor.
A New Jersey Teamsters union has filed a federal lawsuit against Pfizer Inc. alleging that the pharmaceutical company marketed the cholesterol drug Lipitor to people with low risk of heart attacks.
A recent study found that cholesterol-lowering drugs such as Zocor and Lipitor have no affect on the eye in preventing age-related muscular degeneration (AMD). Further review of the data suggested statin drugs might increase the risk of AMD.
Two recent studies have found that cholesterol drugs have no effect on preventing cancer.
The Supreme Court of Canada has given the go ahead for a class action suit against Bayer Inc., the manufacturer of the cholesterol drug Baycol®.
Consumer groups filed a nationwide, class-action lawsuit against Pfizer Inc. on Wednesday over misleading ads for the cholesterol drug Lipitor. The suit, filed in the U.S. District Court in Boston, came a day after the Food and Drug Administration (FDA) approved marketing Lipitor to different patient populations.
An American man and 11 Chinese citizens were arrested in a fake drug plot involving approximately $4.3 million dollars of counterfeit medications. The scheme reportedly spanned 11 countries worldwide.
New York -- The Senate Majority Leader suggested that pharmaceutical companies voluntarily impose a two-year ban on direct-to-consumer advertising.
The Food and Drug Administration (FDA) asked Crestor manufacturer AstraZeneca to revise the warning label of their cholesterol-lowering drug. Despite the revision, some consumer groups are still calling for Crestor to be recalled and banned.
A West Virginia judge delayed the civil case involving companies who sold fake versions of the cholesterol drug Lipitor. The delay was made in light of federal criminal charges being prepared against the same companies.
The Medicines and Healthcare Products Regulatory Agency (MHRA), the executive agency of the Department of Health in Britain, has seized counterfeit packs of the cholesterol drug Lipitor that entered into the supply chain.
Health Canada warned that some patients with pre-existing medical conditions could suffer from muscle damage by taking cholesterol-reducing drugs known as statins.
A recent study has found that contrary to previous research, the cholesterol-lowering statin drug Lipitor does not help severely ill diabetes patients. In fact, the research found that patients on Lipitor were twice as likely to die of stroke.
©2008 Einstein Law All Rights Reserved